Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck & Co's varicella production issues persist

This article was originally published in Scrip

Executive Summary

Merck & Co's manufacturing problems for varicella zoster virus continue to cause supply disruptions, according to the US Centers for Disease Control and Prevention(CDC) in a June update. Merck says that customers should expect shipment delays of as much as six weeks in the coming months for the shingles vaccine Zostavax. Merck began marketing Zostavax in 2006 and last year had sales of $236 million; last month the CDC recommended that people aged 60 and above should receive Zostavax (Scrip No 3364, p 21).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts